ESMO 2017 Activities

Target Audience

Physicians who wish to advance their current knowledge of advanced and metastatic colorectal cancer (mCRC).

 

Learning Objectives

  • Interpret the role of tumor biomarkers in the personalized treatment of CRC.
  • Apply research findings from ESMO 2017 to the selection of first-line mCRC treatment.
  • Evaluate insights from ESMO 2017 on the optimal sequencing of second- and subsequent-line therapy in mCRC.

STO designates this activity for .5 AMA PRA Category 1 Credits™

BEGIN ACTIVITY

Target Audience

Physicians who wish to advance their current knowledge of ovarian cancer.

 

Learning Objectives

  • Evaluate the role of biomarkers in the personalized treatment of ovarian cancer.
  • Apply research findings from ESMO 2017 to first-line ovarian cancer treatment.
  • Incorporate ESMO 2017 data into the management of recurrent ovarian cancer.

STO designates this activity for .5 AMA PRA Category 1 Credits™

 

BEGIN ACTIVITY

Target Audience

Physicians who wish to advance their current knowledge of advanced and metastatic colorectal cancer (mCRC).

 

Learning Objectives

  • Interpret the role of tumor biomarkers in the personalized treatment of CRC.
  • Apply research findings from ESMO 2017 to the selection of first-line mCRC treatment.
  • Evaluate insights from ESMO 2017 on the optimal sequencing of second- and subsequent-line therapy in mCRC.

 

STO designates this activity for .5 AMA PRA Category 1 Credits™

Target Audience

Physicians who wish to advance their current knowledge of ovarian cancer.

 

Learning Objectives

  • Evaluate the role of biomarkers in the personalized treatment of ovarian cancer.
  • Apply research findings from ESMO 2017 to first-line ovarian cancer treatment.
  • Incorporate ESMO 2017 data into the management of recurrent ovarian cancer.

 

STO designates this activity for .5 AMA PRA Category 1 Credits™

Sign up here to be notified of new
CME-certified activities from STO.

Sign up here to be notified of new CME-certified
activities from STO.